Archive · 21 Jan 2026
Lupin Partners with Galenicum for Semaglutide
Lupin, a big medicine company, has teamed up with Galenicum, a company from Spain.
They made a deal to work together on a medicine called Semaglutide, which helps people with diabetes and obesity.
Galenicum will make the medicine, and Lupin will sell it in many countries like Canada, Europe, and parts of Asia and South America.
This deal helps Lupin grow its business in these areas.
The medicine is used to manage diabetes and help people lose weight.
Both companies are excited about this partnership because it will help more people get this important medicine.
Lupin Ltd has signed a licensing and supply agreement with Galenicum Health, SLU for injectable Semaglutide.
Galenicum will handle development, manufacturing, and supply, while Lupin will manage regulatory filings, commercialization, and distribution across 23 countries.
The agreement aims to strengthen Lupin's diabetes and obesity portfolio beyond India and expand its presence in regulated and emerging markets.
Semaglutide is prescribed for Type 2 diabetes and long-term weight management in adults with obesity or overweight conditions.
Lupin shares settled 0.81% lower at Rs 2,160.60 on Tuesday.
- Who
- Lupin Ltd and Galenicum Health, SLU
- What
- Licensing and supply agreement for injectable Semaglutide
- When
- Announced (exact date not specified), expected to be in focus on Wednesday's trade
- Where
- Global markets including Canada, Europe, Southeast Asia, and Latin America
- Why
- To strengthen Lupin's diabetes and obesity portfolio and expand presence in regulated and emerging markets
- Company
- Lupin Ltd
- Partner
- Galenicum Health, SLU
- Product
- Injectable Semaglutide
- Markets
- Canada, Europe, Southeast Asia, Latin America
- Countries
- 23
- Shares Closing Price
- Rs 2,160.60
- Shares Change
- -0.81%
